📊 IRON Key Takeaways
Is IRON a Good Investment? Thesis Analysis
Disc Medicine is a pre-revenue biopharmaceutical company with severe cash burn and no commercial revenue generation. Despite maintaining a strong balance sheet with $91.1M in cash and minimal debt, the company is burning through cash at an unsustainable rate ($181.3M negative free cash flow), indicating critical development-stage risk with an uncertain path to profitability.
Why Buy IRON? Key Strengths
- Strong balance sheet with $739.8M stockholders' equity and minimal debt burden (0.04x debt/equity)
- Substantial cash reserves of $91.1M providing runway for continued operations
- Excellent liquidity position with 21.94x current ratio indicating no near-term solvency concerns
IRON Investment Risks to Consider
- Pre-revenue stage with no commercial product sales generating negative $236M operating income
- Unsustainable cash burn of $180.4M in operating cash flow requiring significant capital depletion
- Clinical-stage development risk with no validated revenue model or commercialization timeline demonstrated
- Negative returns on assets (-26.3%) and equity (-28.7%) reflecting cash burn on capital base
Key Metrics to Watch
- Quarterly operating cash flow burn rate and runway to profitability
- Clinical trial progress and FDA approval milestones for pipeline candidates
- Cash balance trajectory and need for additional financing
- Progress toward first revenue-generating product launch
IRON Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 21.94x current ratio provides a solid financial cushion.
IRON Profitability Ratios
IRON vs Healthcare Sector
How Disc Medicine, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is IRON Overvalued or Undervalued?
Based on fundamental analysis, Disc Medicine, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
IRON Balance Sheet & Liquidity
IRON 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: Disc Medicine, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-3.42 indicates the company is currently unprofitable.
IRON Growth Metrics (YoY)
IRON Capital Allocation
IRON SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for Disc Medicine, Inc. (CIK: 0001816736)
📋 Recent SEC Filings
❓ Frequently Asked Questions about IRON
What is the AI rating for IRON?
Disc Medicine, Inc. (IRON) has an AI rating of SELL with 92% confidence, based on fundamental analysis of SEC EDGAR filings.
What are IRON's key strengths?
Claude: Strong balance sheet with $739.8M stockholders' equity and minimal debt burden (0.04x debt/equity). Substantial cash reserves of $91.1M providing runway for continued operations.
What are the risks of investing in IRON?
Claude: Pre-revenue stage with no commercial product sales generating negative $236M operating income. Unsustainable cash burn of $180.4M in operating cash flow requiring significant capital depletion.
What is IRON's revenue and growth?
Disc Medicine, Inc. reported revenue of N/A.
Does IRON pay dividends?
Disc Medicine, Inc. does not currently pay dividends.
Where can I find IRON SEC filings?
Official SEC filings for Disc Medicine, Inc. (CIK: 0001816736) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is IRON's EPS?
Disc Medicine, Inc. has a diluted EPS of $-6.01.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is IRON a good stock to buy right now?
Based on our AI fundamental analysis in March 2026, Disc Medicine, Inc. has a SELL rating with 92% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is IRON stock overvalued or undervalued?
Valuation metrics for IRON: ROE of -28.7% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy IRON stock in 2026?
Our dual AI analysis gives Disc Medicine, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is IRON's free cash flow?
Disc Medicine, Inc.'s operating cash flow is $-180.4M, with capital expenditures of $933.0K.
How does IRON compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -28.7% (avg: 15%), current ratio 21.94 (avg: 2).